Advanced in Acute Lymphoblastic Leukemia (ALL)
Advanced in Acute Lymphoblastic Leukemia (ALL)
Schneider Children's Hospital, 269-01 76th Avenue, 
New Hyde Park, NY 

Overview

Arlene Redner is a Pediatric Hematologist Oncology provider in New Hyde Park, New York. Dr. Redner is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Optic Glioma, Acute Lymphoblastic Leukemia (ALL), Classical Hodgkin Lymphoma, and Leukemia.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles and participated in 8 clinical trials in the study of Acute Lymphoblastic Leukemia (ALL).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 5 Less Insurance Carriers -

Locations

Schneider Children's Hospital, 269-01 76th Avenue, New Hyde Park, NY 11040

Additional Areas of Focus

Dr. Redner has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


19 Clinical Trials

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
View 18 Less Clinical Trials
Similar Doctors
Elite in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology
Elite in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology

New York University

550 1st Ave, 
New York, NY 
 (15.4 miles away)
Languages Spoken:
English

Elizabeth Raetz is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Raetz is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Distinguished in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology
Distinguished in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology
195 Little Albany St, 
New Brunswick, NJ 
 (43.8 miles away)
Languages Spoken:
English

Peter Cole is a Pediatric Hematologist Oncology provider in New Brunswick, New Jersey. Dr. Cole is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Leukemia, and Classical Hodgkin Lymphoma.

Distinguished in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology
Distinguished in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology
1275 York Ave # H-1407, 
New York, NY 
 (14.5 miles away)
Languages Spoken:
English

Maria Sulis is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Sulis is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, and L1 Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Redner's expertise for a condition
ConditionClose
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile